IPO registrations (S-1, F-1) · Registrants
Vivos Therapeutics, Inc.
- SEC CIK
- 1716166 · filings on EDGAR ↗
- Former names
- Vivos BioTechnologies, Inc. (2017–2017)
- Registration
- Form S-1, first filed 2020-10-09, last 2025-01-29; 7 initial registrations, 7 amendments
- Outcome
- Final prospectus filed 2020-12-14; declared effective 2020-12-10
- Industry (SIC)
- Surgical & Medical Instruments & Apparatus 3841
- Incorporated in
- DE
- Business address
- 7921 SOUTHPARK PLAZA,, SUITE 210, Littleton, CO 80120
- EIN
- 81-3224056
- Ticker
- VVOS (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- Vivos Therapeutics, Inc. on the corporate pages
Offering terms
- Proposed price range
- $5.00–$7.00 per share (S-1/A filed 2020-11-27)
- Final price
- $6.00 per share, within the range (424B4 filed 2020-12-14, an initial public offering)
- Shares sold
- 3,500,000
- Gross proceeds
- $21,000,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol VVOS
- Lead underwriters
- Roth Capital Partners
- Syndicate
- Craig-Hallum; of Contents
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: Vivos Therapeutics Inc Fuzzy (name and state)
- Business registration: VIVOS THERAPEUTICS, INC Fuzzy (name and state)
- Business registration: VIVOS THERAPEUTICS, INC. Fuzzy (name and state)
- Form 5500 plan sponsor: VIVOS THERAPEUTICS, INC. EXACT (EIN (EXACT))
- Form D issuer: Vivos Therapeutics, Inc. EXACT (CIK (EXACT))
- Lobbying client: VIVOS THERAPEUTICS, INC. Fuzzy (name and state)
- SEC filer: Vivos Therapeutics, Inc. EXACT (CIK (EXACT))
Filings 36
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2020-10-09 | S-1 | S-1 (registration) | Vivos Therapeutics, Inc. | 0001493152-20-019231 ↗ |
| 2020-10-26 | S-1/A | S-1/A (amendment) | Vivos Therapeutics, Inc. | 0001493152-20-019967 ↗ |
| 2020-11-19 | S-1/A | S-1/A (amendment) | Vivos Therapeutics, Inc. | 0001493152-20-021982 ↗ |
| 2020-11-27 | S-1/A | S-1/A (amendment) | Vivos Therapeutics, Inc. | 0001493152-20-022584 ↗ |
| 2020-12-10 | S-1MEF | S-1MEF (added securities) | Vivos Therapeutics, Inc. | 0001493152-20-023319 ↗ |
| 2020-12-10 | EFFECT | EFFECT (declared effective) | Vivos Therapeutics, Inc. | 9999999995-20-003474 ↗ |
| 2020-12-14 | 424B4 | 424B4 (final prospectus) | Vivos Therapeutics, Inc. | 0001493152-20-023546 ↗ |
| 2021-04-27 | S-1 | S-1 (registration) | Vivos Therapeutics, Inc. | 0001493152-21-009869 ↗ |
| 2021-05-03 | S-1 | S-1 (registration) | Vivos Therapeutics, Inc. | 0001493152-21-010362 ↗ |
| 2021-05-06 | S-1MEF | S-1MEF (added securities) | Vivos Therapeutics, Inc. | 0001493152-21-010675 ↗ |
| 2021-05-06 | EFFECT | EFFECT (declared effective) | Vivos Therapeutics, Inc. | 9999999995-21-001834 ↗ |
| 2021-05-10 | 424B4 | 424B4 (final prospectus) | Vivos Therapeutics, Inc. | 0001493152-21-010895 ↗ |
| 2021-05-18 | S-1/A | S-1/A (amendment) | Vivos Therapeutics, Inc. | 0001493152-21-012080 ↗ |
| 2021-05-19 | 424B4 | 424B4 (final prospectus) | Vivos Therapeutics, Inc. | 0001493152-21-012285 ↗ |
| 2021-05-19 | EFFECT | EFFECT (declared effective) | Vivos Therapeutics, Inc. | 9999999995-21-002008 ↗ |
| 2022-02-14 | EFFECT | EFFECT (declared effective) | Vivos Therapeutics, Inc. | 9999999995-22-000461 ↗ |
| 2023-01-30 | S-1 | S-1 (registration) | Vivos Therapeutics, Inc. | 0001493152-23-002826 ↗ |
| 2023-02-08 | EFFECT | EFFECT (declared effective) | Vivos Therapeutics, Inc. | 9999999995-23-000326 ↗ |
| 2023-02-10 | 424B1 | 424B1 (final prospectus) | Vivos Therapeutics, Inc. | 0001493152-23-004284 ↗ |
| 2023-11-22 | S-1 | S-1 (registration) | Vivos Therapeutics, Inc. | 0001493152-23-042518 ↗ |
| 2023-11-30 | S-1/A | S-1/A (amendment) | Vivos Therapeutics, Inc. | 0001493152-23-043215 ↗ |
| 2023-12-01 | 424B1 | 424B1 (final prospectus) | Vivos Therapeutics, Inc. | 0001493152-23-043402 ↗ |
| 2023-12-01 | EFFECT | EFFECT (declared effective) | Vivos Therapeutics, Inc. | 9999999995-23-003520 ↗ |
| 2024-04-09 | S-1 | S-1 (registration) | Vivos Therapeutics, Inc. | 0001493152-24-013987 ↗ |
| 2024-04-22 | S-1/A | S-1/A (amendment) | Vivos Therapeutics, Inc. | 0001493152-24-015414 ↗ |
| 2024-04-26 | 424B1 | 424B1 (final prospectus) | Vivos Therapeutics, Inc. | 0001493152-24-016721 ↗ |
| 2024-04-26 | EFFECT | EFFECT (declared effective) | Vivos Therapeutics, Inc. | 9999999995-24-001157 ↗ |
| 2024-08-07 | EFFECT | EFFECT (declared effective) | Vivos Therapeutics, Inc. | 9999999995-24-002456 ↗ |
| 2024-08-08 | 424B1 | 424B1 (final prospectus) | Vivos Therapeutics, Inc. | 0001493152-24-030832 ↗ |
| 2025-01-22 | S-1 | S-1 (registration) | Vivos Therapeutics, Inc. | 0001493152-25-003115 ↗ |
| 2025-01-29 | S-1/A | S-1/A (amendment) | Vivos Therapeutics, Inc. | 0001493152-25-004057 ↗ |
| 2025-01-30 | EFFECT | EFFECT (declared effective) | Vivos Therapeutics, Inc. | 9999999995-25-000248 ↗ |
| 2025-01-31 | 424B1 | 424B1 (final prospectus) | Vivos Therapeutics, Inc. | 0001493152-25-004472 ↗ |
| 2025-09-10 | EFFECT | EFFECT (declared effective) | Vivos Therapeutics, Inc. | 9999999995-25-002902 ↗ |
| 2026-01-07 | EFFECT | EFFECT (declared effective) | Vivos Therapeutics, Inc. | 9999999995-26-000088 ↗ |
| 2026-05-08 | EFFECT | EFFECT (declared effective) | Vivos Therapeutics, Inc. | 9999999995-26-001555 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2020-11-27 | S-1/A | registration statement | $5.00–$7.00 | $4.86 | 3,333,334 | $16,200,003 | Nasdaq VVOS | 3 | primary document; range, price line, shares headline, proceeds computed, cover names 3 | document ↗ |
| 2020-12-14 | 424B4 | final prospectus | $6.00 | 3,500,000 | $21,000,000 | Nasdaq VVOS | 3 | primary document; price sentence, shares headline, proceeds table, cover names 3 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Amman Bradford K. | Officer | Chief Financial Officer; Principal Accounting Officer | 10 | 2020–2026 | |
| Green Ralph Elias | Director | 4 | 2020–2024 | ||
| Huntsman Ronald Kirk | Director,Officer; Director,Officer,TenPercentOwner | Chairman and CEO; Chairman & CEO; Chief Executive Officer | 17 | 2020–2026 | |
| Krammer Anja B | Director | 4 | 2020–2024 | ||
| Lindsay Mark F. | Director | 4 | 2020–2024 | ||
| Singh Gurdev Dave | Director,Officer,TenPercentOwner | Chief Medical Officer | 2 | 2020–2021 | |
| SOKOLOW LEONARD J | Director | 5 | 2020–2026 | ||
| Thompson Matthew | Director | 4 | 2020–2024 | ||
| Skaff Michael C | TenPercentOwner | 3 | 2025–2026 | ||
| JOHNSON GREGG C | Director | 2 | 2026 | ||
| V-Co Investors 3 LLC | TenPercentOwner | 2 | 2026 | ||
| V-Co Investors 4 LLC | TenPercentOwner | 1 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2020-02-20 | Vivos Therapeutics, Inc. | Biotechnology | $18,000,000 | $50,000 | 1 | 1 |
| 2019-05-16 | Vivos Therapeutics, Inc. | Biotechnology | $5,000,000 | $556,500 | 9 | 1 |
| 2017-09-28 | Vivos BioTechnologies, Inc. | Biotechnology | $3,000,000 | $0 | 0 | 2 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | Vivos Therapeutics Inc | CO | State business registries | name and state |
| Business registration | VIVOS THERAPEUTICS, INC | CO | State business registries | name and state |
| Business registration | VIVOS THERAPEUTICS, INC. | CO | State business registries | name and state |
| Plan sponsor | VIVOS THERAPEUTICS, INC. | CO | Form 5500 (employee benefit plans) | EIN (EXACT) |
| Form D issuer | Vivos Therapeutics, Inc. | CO | Form D private offerings | CIK (EXACT) |
| Lobbying client | VIVOS THERAPEUTICS, INC. | CO | Federal lobbying (LDA) | name and state |
| Patent assignee | Vivos Therapeutics, Inc. | CO | Patents (USPTO) | name and state |
| SEC filer | Vivos Therapeutics, Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | Vivos Therapeutics, Inc. | CO | Trademarks (USPTO) | name and state |
| Form 5500 plan sponsor | VIVOS THERAPEUTICS, INC. | EIN (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Surgical & Medical Instruments & Apparatus, CO first:
- HEALTHETECH INC CO
- Sonoma Pharmaceuticals, Inc. CO
- Paragon 28, Inc. CO
- Assure Holdings Corp. CO
- TriSalus Life Sciences, Inc. CO
- SeaStar Medical Holding Corp CO
- FAMILY OFFICE OF AMERICA, INC. CO
- ENCISION INC CO
- SWISSRAY INTERNATIONAL INC NY
- FUSION MEDICAL TECHNOLOGIES INC CA
In other datasets, the same topic (Technology) in CO:
- Form D issuer: 30dB, Inc. (Form D private offerings)
- Lobbying client: 360NETWORKS (Federal lobbying (LDA))
Interests: Surgical & Medical Instruments & Apparatus · Technology